Call Now

Mouse Osteoprotegerin / TNFRSF11B Protein (Fc Tag)

Ocif,Opg,TR1

Catalog Number P52613-M02H
Organism Species Mouse
Host Human Cells
Synonyms Ocif,Opg,TR1
Molecular Weight The recombinant mouse Tnfrsf11b consists 618 amino acids and predicts a molecular mass of 70.2 kDa.
predicted N Glu 22
SDS-PAGE
Purity > 95 % as determined by SDS-PAGE.
Protein Construction A DNA sequence encoding the mouse Tnfrsf11b (NP_032790.3) (Met1-Leu401) was expressed with the Fc region of human IgG1 at the C-terminus.
Bio-activity
Research Area Cardiovascular |Angiogenesis |Cytokines / Chemokines in Angiogenesis |TNF Superfamily |Processes Regulated by TNF Superfamily Members |Regulation of Apoptosis by TNF Superfamily Members |
Formulation Lyophilized from sterile PBS, pH 7.4.
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background Osteoprotegerin or TNFRSF11B is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. Osteoprotegerin/TNFRSF11B acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. This protein may inhibit the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. Osteoprotegerin/TNFRSF11B also play a role in preventing arterial calcification, act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
Reference
  • Collin-Osdoby P. (2005) Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 95 (11): 1046-57.
  • Boyce BF, et al. (2007) Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res. Ther. 9 Suppl 1: S1.
  • Blázquez-Medela AM, et al. ( 2011) Osteoprotegerin and diabetes-associated pathologies. Curr Mol Med. 11 (5): 401-16.